SCYX has been the topic of a number of other reports. Brookline Capital Management reaffirmed a “buy” rating on shares of SCYNEXIS in a research report on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 target price on shares of SCYNEXIS in a research report on Thursday, November 7th. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $6.00 target price on shares of SCYNEXIS in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. SCYNEXIS presently has an average rating of “Buy” and an average price target of $4.13.
NASDAQ SCYX traded down $0.07 during trading on Wednesday, hitting $0.96. The company had a trading volume of 864,600 shares, compared to its average volume of 628,989. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 2.60. SCYNEXIS has a one year low of $0.35 and a one year high of $1.90. The company has a market cap of $60.12 million, a price-to-earnings ratio of -1.96 and a beta of 2.23. The company’s fifty day moving average is $1.13 and its 200-day moving average is $1.16.
SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.
Featured Story: What are the risks of holding treasury bonds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.